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To this end human MSCs were isolated from adipose tissue and the MSC:CD4+ T-cell suppression was assessed in a
co-culture system. In summary, this study demonstrates that advanced age, atherosclerosis and type 2 diabetes
mellitus reduce the functional potency of MSCs. Optimizing the criteria for the selection of MSC donors could
enhance the results of cell-based therapies.Findings
Age and age- associated conditions (type 2 diabetes and
athrosclerosis) decrease the immunomodulatory capacity
of MSCs.
Optimal donor selection and proper immunological
characterization of MSCs are critical for the successful
therapeutic use of MSCs.Introduction
Atherosclerotic ischemic heart disease is the leading
cause of death in developed countries. The preva-
lence, incidence, and severity of atherosclerosis (ATH)
markedly increase with chronological age and in the
context of age-associated chronic inflammatory condi-
tions such as type 2 diabetes mellitus (T2DM) [1].
Chronic inflammation is a key regulatory process that
links multiple risk factors for ATH and its complica-
tions to altered arterial biology. In mature atheroscler-
otic lesions, immune responses mediated by CD4+ T
cells seem to be critical to accelerate atherogenesis
and to promote plaque instability [2]. This is sup-
ported by the correlation between increased circulat-
ing numbers of activated CD4+ T cells and the extent
of ATH in carotid and coronary arteries, and by the* Correspondence: ines.colmegna@mcgill.ca
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pared to those from patients with stable coronary ar-
tery disease [3, 4]. In vivo studies also showed the
arrest in the development and progression of ATH
following T cell-targeted therapy (i.e., anti-CD3Ab)
[5]. The fundamental role of immune-activation in
ATH provides the rationale to develop therapeutic in-
terventions that restore immune homeostasis in ische-
mic heart disease. Among these strategies, the use of
mesenchymal stromal cells (MSCs) showed promise in
preclinical studies and most recently in patients with
nonrevascularizable ischemic myocardium (reviewed
in [6, 7]). Immunosuppressive and anti-inflammatory
effects of MSCs are key mechanisms underlying their
therapeutic effects [8]. A critical aspect linked to the
success of any type of cell therapy is the appropriate se-
lection of donors; however, the effect of donor’s age and
age-associated co-morbidities on human MSC-mediated
T-cell suppression remains undefined [9, 10]. The aim
of this study was to evaluate the impact of chronological
aging and of the age-associated diseases, ATH and
T2DM, on the immunomodulatory capacity of MSCs.Methods
The McGill University Health Center Ethics Review
Board approved the study and participants provided
written informed consent. Subcutaneous adipose tissue
was obtained from patients undergoing programmed
cardiovascular surgery. Table 1 summarizes the demo-
graphics and cardiovascular risk factors of the studiedccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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supplementary data (Additional file 1: Supplementary ma-
terials and methods). Briefly, MSCs were derived from adi-
pose tissue and proven to meet the International Society
for Cellular Therapy definition criteria [11]. Freshly har-
vested, early passage (P4) MSCs were used in all assays.
Peripheral blood mononuclear cells (PBMCs) were ob-
tained from a single unrelated donor, monocyte depleted
(<5 % monocytes) [12], Carboxyfluorescein succinimidyl
ester (CFSE) stained and activated with CD3/CD28 beads.
MSC-dependent CD4+ T-cell suppression was assessed in
co-cultures [13]. Proliferation curves of live CD4+ T cells
were plotted and the suppressive effect of MSCs on T
cells was determined by comparing maximal prolifera-
tion (T cells alone) versus proliferation in co-cultures
(MSCs + T cells) (Additional file 2: Figure S1). Wilcoxon's
Rank Sum test was used for group comparisons. Multiple
linear regression analysis examined the effects of age,
ATH and T2DM on the mean MSC:CD4+ T-cell sup-
pression capacity, after adjusting for the covariates of
interest. Assumptions of the regression model were in-
vestigated with graphical analysis of residuals. All ana-
lyses were performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA). All hypotheses tests were
two-sided and performed at a significance level of 0.05.
Results
MSCs from older donors are less efficient at suppressing
T-cell proliferation
The immunomodulatory capacity of adult MSCs (A-





Sex (female:male, n) 13:28
Age in years, mean (SD) 63.4 (1
Ethnicity (Caucasian:Asian, n) 37:4
Body mass index, mean (SD) 29.1 (9




Type 2 diabetes 12 (29)
Medications, n (%)
Statins 33 (80)
ACE inhibitors/ARB 20 (49)
Beta blockers 26 (63)
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers, ATH atheMSCs, ≥65 years old, n = 23) was examined by analyzing
their ability to inhibit the proliferation of anti-CD3/
CD28-activated CD4+ T cells. The suppressive effect of
A-MSCs and E-MSCs on CD4+ T-cell proliferation was
dose-dependent. At a MSC:T cell ratio of 1:8 (Fig. 1a),
A-MSCs (median 33.9 %, interquartile range (IQR) 6.8–
46.0, n = 27) inhibited activated CD4+ T cells more
effectively than E-MSCs (median 47.5 %, IQR 35.6–58.0,
n = 23) (p < 0.003). Similar results were obtained at
MSC:T cell ratios of 1:14 and 1:20. A-MSCs at 1:14 ratio
(median 50.1 % IQR 37.6–62.2, n = 17) had similar in-
hibitory capacity as E-MSCs at 1:8 ratio, highlighting the
magnitude of the E-MSC defect (Fig. 1b). MSC donor
age positively correlated with T-cell proliferation in both
ATH and non-ATH (samples from patients undergoing
valve replacement surgery) groups (Pearson’s r = 0.4 and
0.7, respectively) (Fig. 1c), indicating an age-associated de-
cline in the MSC immunomodulatory capacity. Similar de-
fects of the E-MSC suppressive ability were observed on
CD8+ T cells (Additional file 3: Figure S2). In a multiple
linear regression model (Table 2), adjusting for covariates
of interest, age had a significant effect on the reduction of
MSC:CD4+ T-cell suppression (p = 0.02), with increasing
mean CD4+ T-cell proliferation of 0.5 % (95 % confidence
interval (CI) 0.1–1.0) for any 1-year increase in age.
ATH and T2DM reduce the immunomodulatory capacity
of MSCs
The effect of biological aging on human MSC-mediated
T-cell suppression was tested by evaluating MSCs from
donors with ATH and T2DM, diseases associated withl procedure















Fig. 1 Age-associated decline in mesenchymal stromal cell (MSC)-mediated CD4+ T-cell suppression capacity. a MSCs from elderly donors
(E-MSCs, ≥65 years, n = 23) are less efficient than those of non-elderly adults (A-MSCs, <65 years, n = 27) to suppress CD4+ T-cell
proliferation at 1:8 MSC:CD4+ T cell ratio (**p = 0.003). b The suppressive effect of MSCs on CD4+ T cells depends on the MSC:CD4+ T-cell ratio
(**p = 0.004). Twice the number of E-MSCs are required to affect CD4+ T-cell suppression to the same extent as A-MSCs (p > 0.9). c The effect
of MSC donor age on the decline of CD4+ T-cell suppression is observed in patients with atherosclerosis (ATH; n = 18; p = 0.02, r = 0.4) and
without ATH (non-ATH; n = 9; p = 0.02, r = 0.7)
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patients undergoing valve replacement surgery who had
a normal pre-surgical coronary angiography (non-ATH
subjects; median 15.6 %, IQR 9.9–42.5, n = 9) had a higher
ability to suppress activated CD4+ T cells compared to
MSCs from ATH age-matched controls (median 44.2,
IQR 36.7–55.7, n = 18) (Fig. 2a). Moreover, in age-
matched ATH patients the diagnosis of T2DM further
reduced the MSC suppressive capacity (median 41.0, IQR
32.3–50.1, and 56.4, IQR 40.8–74.2, for non-T2DM/
T2DM, n = 12, respectively) (Fig. 2b). Unadjusted, age-
matched comparisons of MSC function in a sample subset
(n = 7) suggested that ATH and T2DM were associated
with a reduction in the MSC suppressive capacity (Fig. 2c).
In the multiple regression model (Table 2), the presence/
absence of ATH and T2DM in MSC donors hadTable 2 Results of linear regression analysis of factors
associated with mesenchymal stromal cell immunomodulatory
function
Variable Estimate Standard error T p value
Intercept −5.62 16.28 −0.35 0.73
Presence of ATH 21.61 7.68 2.82 0.01
Presence of T2DM 14.37 5.80 2.48 0.02
Age 0.54 0.23 2.42 0.02
Sex 2.58 5.90 0.44 0.66
Tobacco −4.55 5.72 −0.80 0.43
LVD −1.67 6.76 −0.25 0.81
Statins −9.00 6.96 −1.44 0.16
ACE inhibitors/ARB –4.05 5.72 –0.71 0.48
Beta blockers −5.14 6.42 −0.80 0.43
Entries in bold are statistically significant. ACE angiotensin-converting enzyme,
ARB angiotensin II receptor blockers, LVD left ventricular dysfunction, T2DM
type 2 diabetes mellitussignificant effects on their capacity to suppress prolifer-
ating CD4+ T cells. Subjects with ATH had a higher
mean percentage of proliferating CD4+ T cells (de-
creased MSC:T-cell suppressive capacity) than those
without ATH (mean difference 21.6 %; 95 % CI, 36.1–
37.1). Similarly, subjects with T2DM had a higher mean
percentage of proliferating CD4+ T-cells (mean differ-
ence 14.4 %; 95 % CI, 2.6–26.1). There was no statisti-
cally significant interaction either between ATH and
T2DM or between each of them and age. This suggests
that the effect of ATH is independent of T2DM and
that these effects are also independent of age.
Discussion
The PRECISE trial demonstrated the feasibility, safety
and potential therapeutic benefit of the transendocardial
administration of autologous adipose-derived MSCs in
no-option patients with ischemic cardiomyopathy [7].
This study provided a proof of concept to test MSCs in
larger ongoing clinical trials [6]. However, the improve-
ment of cardiac function varied in preclinical trials. This
emphasizes the need to define determinants of MSC
therapeutic efficiency that will inform on proper donor
selection [7, 14]. Previous data suggest that the aging
process may impair the functional activity of murine
MSCs, limiting their therapeutic potential [15].
Delineating the effects of aging and age-associated con-
ditions on MSC function is critical, since the vast major-
ity of patients that would benefit from MSC use in the
context of ATH are elderly individuals. Notably, a sig-
nificant proportion of this cohort also has T2DM [16].
Furthermore, defining the factors that impact MSC
function would help to identify proper criteria to se-
lect the most therapeutically efficient cells for clinical
applications.
Fig. 2 Reduced MSC-mediated T-cell suppression capacity in patients with atherosclerosis and type 2 diabetes. a MSCs from patients with athero-
sclerosis (ATH; n = 18; *p = 0.02) have a decreased capacity to suppress CD4+ T-cell proliferation at 1:8 MSC:CD4+ T cell ratio compared to age-
matched controls without atherosclerosis (non-ATH, n = 9). b MSCs from patients with ATH (n = 12) and type 2 diabetes mellitus (T2DM) (n = 12)
have impaired suppressive capacity compared to age-matched ATH controls (*p = 0.04). c MSC function is compromised in age-matched patients
with chronic inflammatory diseases (non-ATH < ATH < ATH+T2DM; n = 7 per group; *p = 0.02, **p = 0.002)
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passages 2–4) and freshly harvested MSCs have better
in vitro T-cell suppression capacity and are associated
with more clinical benefits than late-passage and freeze/
thawed MSCs [17]. Our findings suggest that even when
tested under “optimal” conditions (i.e., fresh early-passage
MSCs in a reproducible immunopotency assay [13]), MSCs
from elderly subjects with ATH have impaired T-cell sup-
pression compared to their non-elderly adult counterparts.
Consistent with previous studies [18, 19], this impaired
function was not explained by differences in the MSC pro-
liferative capacity or phenotype. Similar to E-MSCs, MSCs
from donors with ATH and T2DM have reduced MSC-
mediated T-cell suppression, and the coexistence of
these chronic inflammatory conditions further com-
promise MSC function.
The overall efficacy of stem cell transplantation relies
on the activity of donor cells and tissue environment.
Our co-culture model is limited to MSCs and PBMCs
and does not fully simulate all the components of the
in vivo ischemic and inflammatory environment. How-
ever, this system predicts the MSC immunomodulatory
potency, which is the most relevant mechanism for the
therapeutic effect of MSCs [13]. The finding that age,
T2DM and ATH are associated with reduced MSC im-
munomodulatory function is in line with a recent report
suggesting that MSCs from subjects over 60 years of age
have a reduced ability to ameliorate myocardial function
compared to patients younger than 40 years [20]. A reduc-
tion of MSC-secreted angiogenic factors [18], an increased
vulnerability to hypoxic injury [21] and higher levels of
miR-335 are mechanisms proposed to account for the
diminished reparative activities of E-MSCs.
Conclusions
In summary, our results indicate that age and age-
associated conditions (T2DM and ATH) decrease theimmunomodulatory capacity of MSCs, highlighting the
relevance of donor selection and the need for proper im-
munological characterization of MSCs. Understanding
the interplay between aging, MSC function and their
clinical implications remains the only rational path to
the successful therapeutic use of MSCs.Additional files
Additional file 1: Supplementary materials and methods.
(DOCX 46 kb)
Additional file 2: Figure S1. Gating strategy for the MSC:T cell
suppression assay. The capacity of MSCs to suppress proliferative
responses on activated CD4+ T cells was assessed in a 4-day allogeneic
co-culture system. (A) PBMCs expanded for 4 days were used as controls
(‘maximal proliferation’). (B) MSCs from different donors were co-cultured for
4 days with primary monocyte-depleted PBMCs obtained from a single
unrelated donor. At day 4, PBMCs were stained with 7-aminoactinomycin D
(7-AAD), and CD4-APC and flow cytometry was performed. The expansion
index of 7AAD−CD4+ T cells was calculated with FlowJo. The percentage of
CD4+ T-cell proliferation was calculated according to the following formula:
% of Proliferation = (X – Control) / (Maximal Proliferation – Control) × 100,
where X = Expansion index of MSC-CD4+ T cell co-culture for each sample,
Control = Expansion index of non-stimulated CD4+ T cells, and Maximal
Proliferation = Expansion index of CD4+ T cells stimulated with anti-CD3/
CD28 beads in the absence of MSCs. (PPT 538 kb)
Additional file 3: Figure S2. Age-associated reduction in MSC-mediated
CD8+ T-cell suppression. (A) The capacity of MSCs from non-elderly adult
donors (A-MSCs, <65 years, n = 8) to suppress CD8+ T cells is higher than
that of elderly donors (E-MSCs, ≥65 years, n = 8) (*p = 0.04; MSC:CD8+ T cell
ratio of 1:8). (B) The E-MSC:CD8+ T-cell suppressive potency at 1:8 ratio is
similar to that of A-MSCs at 1:14 ratio. (C) Age-dependent decline in
MSC:CD8+ T-cell suppression in ATH patients (p = 0.01, R2 = 0.35). (D)
Correlation of the suppressive effect of MSCs on CD4+ and CD8+ T cells
(p < 0.0001, R2 = 0.7; MSC:T cell ratio of 1:8). (PPT 142 kb)Abbreviations
A-MSC: Adult mesenchymal stromal cell; ATH: Atherosclerosis; CI: Confidence
interval; E-MSC: Elderly mesenchymal stromal cell; IQR: Interquartile range;
MSC: Mesenchymal stromal cell; non-ATH: Non-atherosclerosis (samples from
patients undergoing valve replacement surgery); PBMC: Peripheral blood
mononuclear cell; T2DM: Type 2 diabetes mellitus.
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